Cargando…
SUN-171 Glargine Use in a Neonatal Diabetic
BACKGROUND Neonatal Diabetes (ND) is rare with incidence estimated at 1 / 100,000-500,000 live births. Duration of ND and insulin requirements vary with average therapy lasting 3 months. Genetic mutations are reported in 90% of transient forms with mutations in the region of 6q24 accounting for 70%...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552982/ http://dx.doi.org/10.1210/js.2019-SUN-171 |